No clinical evidence Despite bold claims about weight loss and appetite suppression, Peaka GLP-1 has never been the subject of a clinical trial
Available from: Dzaye O, Berning P, Razavi AC, Adhikari R, Jha K, Nasir K et al (2022) Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: an infodemiological study
Janoshik Lab Lab Result: Retatrutide 10mg RET23 Avg
At their six-month dermatology review, their EASI score has dropped significantly and theyve reduced their topical corticosteroid use by roughly half
The difference between 8 mg and 12 mg at 48 weeks was 1.4 percentage points (22.8% vs 24.2%)
For most questions about dosing or side effects, that turnaround is quite fast